Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Work In Process (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Work In Process for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Work In Process fell 41.48% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 41.48% year-over-year, with the annual reading at $1.4 million for FY2025, 75.88% down from the prior year.
  • Work In Process for Q4 2025 was $1.8 million at Aytu Biopharma, up from $862000.0 in the prior quarter.
  • The five-year high for Work In Process was $5.7 million in Q2 2024, with the low at $862000.0 in Q3 2025.
  • Average Work In Process over 5 years is $2.8 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Work In Process skyrocketed 93.67% in 2024, then plummeted 75.88% in 2025.
  • Over 5 years, Work In Process stood at $2.2 million in 2021, then grew by 28.99% to $2.8 million in 2022, then dropped by 4.6% to $2.7 million in 2023, then increased by 16.04% to $3.1 million in 2024, then crashed by 41.48% to $1.8 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $1.8 million, $862000.0, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.